Christophe Hennequin

ORCID: 0000-0002-4528-927X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antifungal resistance and susceptibility
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Fungal Infections and Studies
  • Plant Pathogens and Fungal Diseases
  • Breast Cancer Treatment Studies
  • Lung Cancer Treatments and Mutations
  • Bladder and Urothelial Cancer Treatments
  • Colorectal and Anal Carcinomas
  • Lymphoma Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Nail Diseases and Treatments
  • Gastric Cancer Management and Outcomes
  • Urologic and reproductive health conditions
  • Colorectal Cancer Surgical Treatments
  • Infectious Diseases and Mycology
  • Lung Cancer Diagnosis and Treatment
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Cancer Treatment and Pharmacology
  • Breast Lesions and Carcinomas
  • Head and Neck Cancer Studies
  • Esophageal Cancer Research and Treatment
  • Fungal and yeast genetics research
  • Lung Cancer Research Studies
  • Tracheal and airway disorders

Centre de Recherche Saint-Antoine
2015-2025

Hôpital Saint-Antoine
2016-2025

Inserm
2016-2025

Sorbonne Université
2016-2025

Assistance Publique – Hôpitaux de Paris
2016-2025

Hôpital Saint-Louis
2016-2025

Université Paris Cité
2016-2025

Sorbonne Paris Cité
2017-2024

Institut Bergonié
2024

Institut Franco-Allemand de Recherches de Saint-Louis
2014-2022

Purpose Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified and oxaliplatin. Patients Methods We randomly assigned patients to receive 5 weeks of treatment 45 Gy/25 fractions concurrent 800 mg/m 2 twice daily days per week (Cap 45) or 50 oxaliplatin once weekly (Capox 50). The primary end point was complete sterilization the operative specimen (ypCR). Results...

10.1200/jco.2009.25.8376 article EN Journal of Clinical Oncology 2010-03-02

Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical up-to-dated guidelines on management MPM. To obtain an earlier reliable diagnosis MPM, recommend performing thoracoscopy, except in cases pre-operative contraindication or symphysis. The standard staining procedures are insufficient approximately 10%...

10.1183/09031936.00063109 article EN European Respiratory Journal 2010-03-01

The ACCORD 12 trial investigated the value of two different preoperative chemoradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer. Clinical results are reported after follow-up 3 years.Between November 2005 and July 2008, a total 598 patients were randomly assigned to CT-RT with CAP45 (45-Gy RT for 5 weeks concurrent capecitabine) or CAPOX50 (50-Gy capecitabine oxaliplatin). Total mesorectal excision was planned 6 CT-RT. primary end point sterilization operative specimen,...

10.1200/jco.2012.42.8771 article EN Journal of Clinical Oncology 2012-10-30

Concomitant radiochemotherapy (RCT) is the standard for locally advanced anal canal carcinoma (LAACC). Questions regarding role of induction chemotherapy (ICT) and a higher radiation dose in LAACC are pending. Our trial was designed to determine whether escalation boost or two cycles ICT before concomitant RCT lead an improvement colostomy-free survival (CFS).Patients with tumors ≥ 40 mm, < mm N1-3M0 were randomly assigned one four treatment arms: (A) (fluorouracil 800 mg/m(2)/d intravenous...

10.1200/jco.2011.35.4837 article EN Journal of Clinical Oncology 2012-04-24

Pneumocystis jirovecii pneumonia (PCP) in patients without AIDS is increasingly common. We conducted a prospective cohort study of consecutive with proven PCP; 544 patients, 223 (41%) had (AIDS patients) and 321 (59%) other immunosuppressive disorders (non-AIDS patients). Fewer than non-AIDS required intensive care or ventilation, the rate hospital deaths--17.4% overall--was significantly lower for versus (4% vs. 27%; p<0.0001). Multivariable analysis showed odds death increased older age,...

10.3201/eid2009.131668 article EN cc-by Emerging infectious diseases 2014-07-31

The clinical significance of Candida cultured from peritoneal fluid specimens remains a matter debate. None the studies that have addressed this issue clearly distinguished between community-acquired peritonitis and nosocomial peritonitis. current study tried to differentiate pathogenic role in these two settings assess its importance on outcome.A multiple-center, retrospective, case-control was conducted intensive care unit patients. interaction mortality rates type patients assessed. In...

10.1097/01.ccm.0000201889.39443.d2 article EN Critical Care Medicine 2006-02-22

Since Saccharomyces cerevisiae appears to be an emerging pathogen, there is a need for valuable molecular marker able distinguish among strains. In this work, we investigated the potential value of microsatellite length polymorphism with panel 91 isolates, including 41 clinical 14 laboratory strains, and 28 strains industrial relevance. Testing seven polymorphic regions (five trinucleotide repeats two dinucleotide repeats) in subgroup 58 unrelated identified total 69 alleles (6 13 per locus)...

10.1128/jcm.39.2.551-559.2001 article EN Journal of Clinical Microbiology 2001-02-01

Summary The pathogenic yeast Candida glabrata is able to bind in vitro human epithelial cells. This interaction depends on expression of the adhesin Epa1p. genome contains a number EPA1 paralogues which localize subtelomeric regions C. . We have identified three hyperadherent mutants first has an insertion adjacent EPA7 , ‐related adhesin. others disrupt SIR3 and RIF1 genes show that are required for silencing regulates telomere length phenotype sir3 Δ rif1 deletion strains primarily...

10.1111/j.1365-2958.2004.04465.x article EN Molecular Microbiology 2005-01-12

Candida glabrata follows C. albicans as the second or third most prevalent cause of candidemia worldwide. These two pathogenic yeasts are distantly related, being part Nakaseomyces, a group more closely related to Saccharomyces cerevisiae. Although was thought be only new pathogens have recently been described within this group: nivariensis and bracarensis. To gain insight into genomic changes underlying emergence virulence, we sequenced genomes these two, three other non-pathogenic compared...

10.1186/1471-2164-14-623 article EN cc-by BMC Genomics 2013-01-01

MALDI-TOF MS can be used for the identification of microorganism species. We have extended its application to a novel assay Candida albicans susceptibility fluconazole, based on monitoring modifications proteome yeast cells grown in presence varying drug concentrations. The method was accurate, and reliable, showed full agreement with Clinical Laboratory Standards Institute's reference method. This proof-of-concept demonstration highlights potential this approach test other pathogens.

10.1002/pmic.200900152 article EN PROTEOMICS 2009-09-11

The prognosis of patients with locally advanced breast cancer (LABC) remains poor. We prospectively investigated the impact <sup>18</sup>F-FDG PET/CT at initial staging in this clinical setting and compared performance that conventional distant work-up. <b>Methods:</b> During 60 mo, consecutive LABC (clinical T4 or N2–N3 disease) underwent PET/CT. yield was assessed whole group separately for noninflammatory inflammatory cancer. a approach including bone scanning, chest radiography,...

10.2967/jnumed.112.106864 article EN Journal of Nuclear Medicine 2012-12-04
Coming Soon ...